載入中
aTyr Pharma, Inc., a biopharmaceutical firm established in San Diego, California, in 2005, is dedicated to the discovery and advancement of therapeutic solutions. Operating within the United States, the company's research focuses on pioneering novel immunological pathways to address various medical conditions. Its primary investigational drug, efzofitimod, functions as a selective modulator of NRP2. This compound is currently undergoing a Phase III clinical trial for pulmonary sarcoidosis. Additionally, efzofitimod is being evaluated in a Phase 1b/2a clinical study for the treatment of other interstitial lung diseases (ILDs), including conditions such as chronic hypersensitivity pneumonitis and ILDs linked to connective tissue diseases. Beyond its lead candidate, aTyr Pharma's pipeline features ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical stages of development for combating fibrosis. The company is also progressing with ATYR0750, a domain sourced from alanyl-tRNA synthetase, intended for the management of liver disorders. Furthermore, aTyr Pharma has entered into a strategic collaboration and licensing agreement with Kyorin Pharmaceutical Co., Ltd. This partnership is focused on the development and commercialization of efzofitimod for interstitial lung diseases specifically within the Japanese market.
收盤時
US$0.2011
−US$0.0137 · -6.38%
盤後
US$0.2012
+US$0.0001 · +0.05%
10月13日 下午4:25 ET
盤中時間採用ET。市場資料可能有所延遲。
aTyr Pharma, Inc., a biopharmaceutical firm established in San Diego, California, in 2005, is dedicated to the discovery and advancement of therapeutic solutions. Operating within the United States, the company's research focuses on pioneering novel immunological pathways to address various medical conditions. Its primary investigational drug, efzofitimod, functions as a selective modulator of NRP2. This compound is currently undergoing a Phase III clinical trial for pulmonary sarcoidosis. Additionally, efzofitimod is being evaluated in a Phase 1b/2a clinical study for the treatment of other interstitial lung diseases (ILDs), including conditions such as chronic hypersensitivity pneumonitis and ILDs linked to connective tissue diseases. Beyond its lead candidate, aTyr Pharma's pipeline features ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical stages of development for combating fibrosis. The company is also progressing with ATYR0750, a domain sourced from alanyl-tRNA synthetase, intended for the management of liver disorders. Furthermore, aTyr Pharma has entered into a strategic collaboration and licensing agreement with Kyorin Pharmaceutical Co., Ltd. This partnership is focused on the development and commercialization of efzofitimod for interstitial lung diseases specifically within the Japanese market.
日內區間
目前US$0.2011
52週區間
目前US$0.2011
盤中時間採用ET。市場資料可能有所延遲。
aTyr Pharma, Inc., a biopharmaceutical firm established in San Diego, California, in 2005, is dedicated to the discovery and advancement of therapeutic solutions. Operating within the United States, the company's research focuses on pioneering novel immunological pathways to address various medical conditions. Its primary investigational drug, efzofitimod, functions as a selective modulator of NRP2. This compound is currently undergoing a Phase III clinical trial for pulmonary sarcoidosis. Additionally, efzofitimod is being evaluated in a Phase 1b/2a clinical study for the treatment of other interstitial lung diseases (ILDs), including conditions such as chronic hypersensitivity pneumonitis and ILDs linked to connective tissue diseases. Beyond its lead candidate, aTyr Pharma's pipeline features ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical stages of development for combating fibrosis. The company is also progressing with ATYR0750, a domain sourced from alanyl-tRNA synthetase, intended for the management of liver disorders. Furthermore, aTyr Pharma has entered into a strategic collaboration and licensing agreement with Kyorin Pharmaceutical Co., Ltd. This partnership is focused on the development and commercialization of efzofitimod for interstitial lung diseases specifically within the Japanese market.
日內區間
目前US$0.2011
52週區間
目前US$0.2011
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 19萬 USD | 23.5萬 USD | 35.3萬 USD | 1038.6萬 USD | — |
| 銷貨成本 | 155.3萬 USD | — | — | 169.5萬 USD | 130.4萬 USD |
| 毛利 | −136.3萬 USD | 23.5萬 USD | 35.3萬 USD | 869.1萬 USD | −130.4萬 USD |
| 研究與開發 | 6021.9萬 USD | 5437.2萬 USD | 4229.3萬 USD | 4280.8萬 USD | 2326.4萬 USD |
| 銷售、一般及管理費用 | 1759.8萬 USD | 1377.7萬 USD | 1297.9萬 USD | 1228.7萬 USD | 1075.1萬 USD |
| 營業費用 | 7626.4萬 USD | 6814.9萬 USD | 5527.2萬 USD | 5509.5萬 USD | 3271.1萬 USD |
| 折舊和攤銷 | 155.3萬 USD | 154萬 USD | 274.1萬 USD | 169.5萬 USD | 130.4萬 USD |
| 營業利益 | −7762.7萬 USD | −6791.4萬 USD | −5491.9萬 USD | −4640.4萬 USD | −3401.5萬 USD |
| 淨利 | −7411.8萬 USD | −6402.3萬 USD | −5038.9萬 USD | −4533.8萬 USD | −3376.8萬 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$5.13
上漲空間 2450.97%| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2019年7月1日 | 1:14 | — | — |
已生效 2019年7月1日
1:14
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
